Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Operating Expenses | 4,985 | 4,539 | 2,186 | 4,153 | 6,664 |
| Operating Income | -4,985 | -4,539 | -4,406 | -4,153 | -6,664 |
| Interest Expense | 47 | 20 | -51 | 14 | 18 |
| Other Income | 244 | 173 | 132 | 25 | 30 |
| Pre-tax Income | -4,787 | -4,386 | -4,223 | -4,141 | -6,652 |
| Net Income Continuous | -4,787 | -4,386 | -4,223 | -4,141 | -6,652 |
| Net Income Discontinuous | 130 | 55 | 98 | 294 | -240 |
| Net Income | $-4,658 | $-4,331 | $-4,125 | $-3,848 | $-6,891 |
| EPS Basic Total Ops | -0.09 | -0.08 | -0.09 | -0.07 | -0.14 |
| EPS Basic Continuous Ops | -0.09 | -0.08 | -0.08 | -0.08 | -0.13 |
| EPS Basic Discontinuous Ops | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| EPS Diluted Total Ops | -0.09 | -0.08 | -0.09 | -0.07 | -0.14 |
| EPS Diluted Continuous Ops | -0.09 | -0.08 | -0.08 | -0.08 | -0.13 |
| EPS Diluted Discontinuous Ops | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| EPS Diluted Before Non-Recurring Items | -0.09 | -0.08 | N/A | N/A | N/A |
| EBITDA(a) | $-4,985 | $-4,539 | $-2,264 | $-4,119 | $-6,621 |